Our patent-pending technology, BIO-IMS, detects anomalies at the cellular level during the absolute earliest stages of disease genesis. By shifting the clinical paradigm from reactive management to proactive interception, our goal is to pave the way for curative pathways rather than allowing conditions to degenerate into chronic illnesses.
While conventional diagnostics rely on rigid protocols and late-stage symptomatic indicators, BIO-IMS captures the full spectrum of patient-specific biochemical signals. This high-definition molecular insight empowers clinicians to deliver precise, timely, and evidence-based interventions while continuously monitoring treatment efficacy in real time.
Bypassing the limitations of rigid, predefined biological panels. Our platform captures the full, patient-specific spectrum of abnormal biochemical signals to deliver complete diagnostic accuracy.
Identifying life-altering disease processes at the molecular origin long before physical symptoms appear. We catch cellular anomalies when they are just a cluster of 100 cells, rewriting the diagnostic timeline.
A single, versatile platform technology built to scale effortlessly across multiple clinical domains. From oncology to respiratory care, BIO-IMS standardizes advanced early detection under one core methodology.
Eliminating complex protocols with high-speed, patient-friendly testing. Designed for absolute versatility, the platform is perfectly optimized for immediate deployment in both premium clinical labs and localized community health settings.
Democratizing early diagnostics by overcoming geographic and structural barriers. Our highly mobile architecture brings institutional-grade biochemical insights directly to point-of-care environments worldwide.
Traditional blood tests and liquid biopsies are fundamentally reactive—they look for late-stage circulating biomarkers or tumor DNA shed into the bloodstream after a disease has already caused notable damage. Kidod’s patent-pending BIO-IMS platform maps microscopic volatile shifts at the immediate cellular origin. This allows us to capture the full spectrum of abnormal biochemical signals when a condition is just 100 cells small—years before traditional liquid biopsies would trigger a positive result.
The platform is custom-engineered for rapid, point-of-care execution. Because BIO-IMS isolates target volatile molecules dynamically without requiring slow laboratory culturing, heavy cell staining, or complex genetic sequencing cycles, diagnostic insights can be generated within minutes. This rapid processing enables immediate, evidence-based triage and continuous clinical monitoring.
By completely eliminating the need for expensive lab infrastructure, continuous cold-chain sample shipping, and highly specialized lab technicians, BIO-IMS radically lowers the cost per test. Our objective is to deliver institutional-grade molecular accuracy at a fraction of current market costs, making advanced preventive medicine scalable for both premium private clinics and public community healthcare networks worldwide.
No advanced laboratory training or specialized engineering backgrounds are needed. The user experience is designed for seamless, decentralized clinical access. Nurses, dental hygienists, or general medical assistants can easily capture non-invasive patient samples and navigate the automated processing software via a highly intuitive interface.
BIO-IMS is a non-invasive, highly adaptable platform technology. Depending on the targeted clinical application—whether screening for oncology anomalies, complex vaginal flora changes, or respiratory pathogens—the device evaluates accessible, painless matrices like oral saliva, localized swabs, urine analysis.
Yes. One of the primary advantages of our platform is its software-driven adaptability. Because the core hardware tracks fundamental molecular shifts rather than a single fixed bio-indicator, the platform can be recalibrated via software overlays. This ensures that clinical providers can continuously update their diagnostic capabilities to detect new variants or entirely new disease matrices without buying new machinery.
